main content start
Soliqua 100/33 combines long-acting insulin glargine with the GLP-1 receptor agonist lixisenatide. The insulin helps glucose enter the cells to be used as fuel. The GLP-1 receptor agonist helps release insulin when blood glucose is high and lowers the amount of glucose produced by the liver. This drug is not recommended for use in conjunction with additional bolus (mealtime) insulin therapy. Medications in the GLP-1 receptor agonist class may offer heart and kidney benefits for people with cardiovascular disease.
Soliqua 100/33 is approved for adults with type 2 diabetes.
- Soliqua 100/33 combines insulin glargine (long-acting insulin) and lixisenatide (GLP-1 agonist) to enhance blood glucose management in adults with type 2 diabetes
- Given as a once-daily subcutaneous injection within one hour before the first meal, using a prefilled SoloStar pen (15–60 units daily, max 60 units)
- Clinical studies show it reduces A1C by 1.1–1.6% and fasting blood glucose by 5.7–59.1 mg/dL over 30 weeks
- Unlike insulin alone, may lead to slight weight loss (0.1–0.3 kg), due to lixisenatide’s effect on satiety and gastric emptying
- Common side effects include: hypoglycemia, nausea, injection site reactions, diarrhea or constipation.
Soliqua 100/33 Specs
Key specification
Generic Name
Insulin Glargine + Lixisenatide
Drug Class
Insulin + GLP-1 receptor agonists
Type
Injected
General Information
Product Name
Soliqua 100/33
Product Type
Injectable Medications
Brand
Sanofi
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
